November 2021 Br J Cardiol 2021;28:155–62 doi:10.5837/bjc.2021.051
Rea Ganatra, Robert Smith
Introduction In western populations, mitral regurgitation (MR) is the second most common valvular heart disorder, after aortic stenosis, with a reported prevalence of approximately 2%. This prevalence increases with age and affects up to 10% of those over the age of 75.1,2 Severe MR tends to run an insidious yet malignant course and, without intervention, confers a poor prognosis. Untreated, it is associated with progressive left ventricular remodelling, and ultimately dysfunction, resulting in increased morbidity and an annual mortality rate of 5%.3-5 Mitral valve surgery (MVS), typically mitral valve repair (MVr), for severe degenerative MR
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits